BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ng CH, Lin SY, Chin YH, Lee MH, Syn N, Goh XL, Koh JH, Quek J, Hao Tan DJ, Mok SF, Tan E, Dan YY, Chew N, Khoo CM, Siddiqui MS, Muthiah M. Antidiabetic Medications for Type 2 Diabetics with Nonalcoholic Fatty Liver Disease: Evidence From a Network Meta-Analysis of Randomized Controlled Trials. Endocr Pract 2021:S1530-891X(21)01244-1. [PMID: 34606980 DOI: 10.1016/j.eprac.2021.09.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Zou C, Sun Y, Liang J. Comparative efficacy of diabetes medications on liver enzymes and fat fraction in patients with nonalcoholic fatty liver disease: a network meta-analysis. Clinics and Research in Hepatology and Gastroenterology 2022. [DOI: 10.1016/j.clinre.2022.102053] [Reference Citation Analysis]
2 Khan A, Ross HM, Parra NS, Chen SL, Chauhan K, Wang M, Yan B, Magagna J, Beiriger J, Shah Y, Shahzad T, Halegoua-demarzio D. Risk Prevention and Health Promotion for Non-Alcoholic Fatty Liver Diseases (NAFLD). Livers 2022;2:264-282. [DOI: 10.3390/livers2040022] [Reference Citation Analysis]
3 Fu CE, Ng CH, Yong JN, Chan KE, Xiao J, Nah B, Bong SHS, Win KM, Bwa AH, Lim WH, Tan DJH, Zeng RW, Chew N, Teng ML, Siddiqui MS, Oben JA, Sanyal AJ, Wai-sun Wong V, Noureddin M, Muthiah M. A Meta-Analysis on Associated Risk of Mortality in Non-Alcoholic Fatty Liver Disease (NAFLD). Endocrine Practice 2022. [DOI: 10.1016/j.eprac.2022.10.007] [Reference Citation Analysis]
4 Salah HM, Fudim M. Sodium-glucose Cotransporter 2 Inhibitors and Nonalcoholic Fatty Liver Disease. Heart Failure Clinics 2022;18:625-634. [DOI: 10.1016/j.hfc.2022.03.011] [Reference Citation Analysis]
5 Muthiah M, Ng CH, Chan KE, Fu CE, Lim WH, Tan DJH, Nah B, Kong G, Xiao J, Yong JN, Tan B, Syn N, Wang J, Sayed N, Tan E, Chew NW, Dan YY, Siddiqui MS, Sanyal AJ, Noureddin M. Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus Non-alcoholic fatty liver disease: a longitudinal cohort analysis. Annals of Hepatology 2022. [DOI: 10.1016/j.aohep.2022.100762] [Reference Citation Analysis]
6 Ng CH, Teng ML, Chew NW, Chan KE, Yong JN, Quek J, Tan DJH, Lim WH, Lee GSJ, Wong J, Kaewdech A, Huang DQ, Wang J, Chan MY, Noureddin M, Siddiqui MS, Sanyal A, Muthiah M. Statins decrease overall mortality and cancer related mortality but are underutilized in NAFLD: a longitudinal analysis of 12,538 individuals. Expert Review of Gastroenterology & Hepatology. [DOI: 10.1080/17474124.2022.2119128] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Chou OHI, Ning J, Chiu Chan RN, Chung CT, Huang H, Ng K, Dee EC, Lee S, Kaewdech A, Liu T, Jing F, Yung Cheung BM, Tse G, Zhou J. Lower risks of sodium glucose cotransporter 2 (SGLT2) inhibitors compared to dipeptidyl peptidase-4 (DPP4) inhibitors for new-onset non-alcoholic fatty liver disease and hepatocellular carcinoma in type 2 diabetes mellitus: A population-based study.. [DOI: 10.1101/2022.08.16.22278847] [Reference Citation Analysis]
8 Chew NWS, Ng CH, Muthiah MD, Sanyal AJ. Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease. Curr Atheroscler Rep 2022. [PMID: 35507280 DOI: 10.1007/s11883-022-01027-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
9 Polyzos SA, Goulis DG, Giouleme O, Germanidis GS, Goulas A. Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease. Curr Obes Rep 2022. [PMID: 35501557 DOI: 10.1007/s13679-022-00474-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Ng CH, Muthiah MD, Xiao J, Chin YH, Lim G, Lim WH, Tay P, Tan DJH, Yong JN, Pan XH, Koh JWH, Chew N, Syn N, Tan E, Huang DQ, Siddiqui MS, Loomba R, Sanyal AJ, Noureddin M. Meta-analysis: analysis of mechanistic pathways in the treatment of non-alcoholic steatohepatitis. Evidence from a Bayesian network meta-analysis. Aliment Pharmacol Ther 2022;55:1076-87. [PMID: 35285529 DOI: 10.1111/apt.16808] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
11 Drożdż K, Nabrdalik K, Hajzler W, Kwiendacz H, Gumprecht J, Lip GYH. Metabolic-Associated Fatty Liver Disease (MAFLD), Diabetes, and Cardiovascular Disease: Associations with Fructose Metabolism and Gut Microbiota. Nutrients 2021;14:103. [PMID: 35010976 DOI: 10.3390/nu14010103] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]